000650 仁和药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)5.4899.66910.41812.81413.040
总资产报酬率 ROA (%)4.3557.5247.90010.01810.075
投入资产回报率 ROIC (%)5.2869.2729.89912.38812.825

边际利润分析
销售毛利率 (%)38.35837.12236.61737.97539.224
营业利润率 (%)23.03517.85818.49821.00820.610
息税前利润/营业总收入 (%)22.54117.36718.05619.83820.104
净利润/营业总收入 (%)17.45512.50813.80816.20615.763

收益指标分析
经营活动净收益/利润总额(%)82.811109.81599.10295.10192.450
价值变动净收益/利润总额(%)1.5498.4657.1763.0408.210
营业外收支净额/利润总额(%)-0.5400.0250.029-0.243-1.481

偿债能力分析
流动比率 (X)5.2406.1033.9344.1875.422
速动比率 (X)4.8205.5093.5413.5664.773
资产负债率 (%)12.54710.61415.88814.2010.115
带息债务/全部投入资本 (%)4.5221.5135.2613.5522.609
股东权益/带息债务 (%)2,098.3326,466.0671,785.7632,708.7513,723.174
股东权益/负债合计 (%)623.795758.439473.282538.965698.005
利息保障倍数 (X)-60.912-35.063-40.342-17.724-97.835

营运能力分析
应收账款周转天数 (天)43.15926.85026.59026.49627.348
存货周转天数 (天)52.73551.44558.36562.71868.424